Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Conversation logo

When electronic cigarettes (e-cigarettes) first emerged, they became a popular way for people to quit smoking. But in 2019, a mysterious lung condition emerged that primarily affected young people, particularly those who vaped. This left many questioning the safety of e-cigarettes.

The condition was named e-cigarettes or vaping use-associated lung injury – or Evali for short. The average (median) age of people affected by the condition was 24 years. Symptoms included respiratory complaints, such as a cough, shortness of breath and chest pain, as well as stomach problems, fever, chills and weight loss.

We now know that Evali is not caused by regulated, commercial nicotine e-cigarettes. Rather, the condition has been linked to products sold as THC-containing e-liquids. Because THC (the active ingredient in cannabis) is expensive, some sellers were cutting their products with vitamin E acetate to make the e-liquid look like it contained more THC than it did. Although vitamin E acetate is an ingredient in some foods and skincare products, it’s harmful when inhaled.

Read the full article on The Conversation website, written by Jamie Hartmann-Boyce, Associate Professor in Nuffield Department of Primary Care Health Sciences.

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.